26 April 2024 false No description of principal activity Taxfiler 2024.6 true 15683135 business:PrivateLimitedCompanyLtd 2024-04-26 2025-04-30 15683135 2024-04-25 15683135 2024-04-26 2025-04-30 15683135 business:AuditExempt-NoAccountantsReport 2024-04-26 2025-04-30 15683135 business:FilletedAccounts 2024-04-26 2025-04-30 15683135 2025-04-30 15683135 business:Director1 2024-04-26 2025-04-30 15683135 business:Director2 2024-04-26 2025-04-30 15683135 business:RegisteredOffice 2024-04-26 2025-04-30 15683135 core:WithinOneYear 2025-04-30 15683135 core:ShareCapital core:PreviouslyStatedAmount 2025-04-30 15683135 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2025-04-30 15683135 core:PreviouslyStatedAmount 2025-04-30 15683135 business:SmallEntities 2024-04-26 2025-04-30 15683135 countries:EnglandWales 2024-04-26 2025-04-30 15683135 core:LandBuildings 2024-04-25 15683135 core:LandBuildings 2024-04-26 2025-04-30 15683135 core:LandBuildings 2025-04-30 15683135 core:WithinOneYear 2024-04-26 2025-04-30 iso4217:GBP xbrli:pure
Company Registration No. 15683135 (England and Wales)
Cell Cell Limited Unaudited accounts for the period from 26 April 2024 to 30 April 2025
Cell Cell Limited Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
Cell Cell Limited Company Information for the period from 26 April 2024 to 30 April 2025
Directors
CHENG, Ka Wai HO, Ka Ki
Company Number
15683135 (England and Wales)
Registered Office
128 City Road London EC1V 2NX United Kingdom
- 3 -
Cell Cell Limited Statement of financial position as at 30 April 2025
2025
Notes
£
Fixed assets
Tangible assets
4
263,312
Current assets
Debtors
5
617
Cash at bank and in hand
6,081
6,698
Creditors: amounts falling due within one year
6
(268,726)
Net current liabilities
(262,028)
Net assets
1,284
Capital and reserves
Called up share capital
2
Profit and loss account
1,282
Shareholders' funds
1,284
For the period ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 21 January 2026 and were signed on its behalf by
HO, Ka Ki Director Company Registration No. 15683135
- 4 -
Cell Cell Limited Notes to the Accounts for the period from 26 April 2024 to 30 April 2025
1
Statutory information
Cell Cell Limited is a private company, limited by shares, registered in England and Wales, registration number 15683135. The registered office is 128 City Road, London, EC1V 2NX, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
Basis of preparation
The financial statements have been prepared on historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at the fair value through profit or loss.
Presentation currency
The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
The company meets its day-to-day working capital requirements through the continued support of its shareholders for the foreseeable future, and at least 12 months from the date of signing of these financial statements. On this basis the director considers that it is appropriate to prepare the financial statements on the going concern basis.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets and depreciation
Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognized in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognized in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognized in other comprehensive income to the extent of any previously recognized revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognized in profit or loss. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives: No depreciation is provided for freehold and/or leasehold land and buildings. If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
- 5 -
Cell Cell Limited Notes to the Accounts for the period from 26 April 2024 to 30 April 2025
Related parties
A related party is a person or entity that is related to the Company in these financial statements, as follows: (a) the party is a person or a close member of that person’s family and that person: (i) has control or joint control over the Company; (ii) has significant influence over the Company; or (iii) is a member of the key management personnel of the Company or of a parent of the Company. or (b) An entity is related to the Company if any of the following conditions applies: (i) the entity and the Company are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others); (ii) one entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member); (iii) both entities are joint ventures of the same third party; (iv) one entity is a joint venture of a third entity and the other entity is an associate of the third entity; (v) the entity is a post-employment benefit plan for the benefit of employees of either the Company or an entity related to the Company. If the Company is itself such a plan, the sponsoring employers are also related to the Company; (vi) the entity is controlled or jointly controlled by a person identified in (a); (vii) a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); and (viii) the entity, or any member of a group of which it is a part, provides key management personnel services to the Company or to the Company’s parent. Close members of the family of a person are those family members who may be expected to influence, or be influenced by, that person in their dealings with the entity.
Foreign Currency Translation
Foreign currency transactions are translated into the functional currency using the spot exchange rate at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses arising in the settlement of transactions and in the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges. Foreign exchange gains and losses related to borrowings and cash equivalents are presented in the profit and loss account under "finance income or costs". All other foreign exchange gains and losses are presented in the profit or loss under "other operating income" or “administrative expenses”.
- 6 -
Cell Cell Limited Notes to the Accounts for the period from 26 April 2024 to 30 April 2025
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in nonconvertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship. Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date. Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
- 7 -
Cell Cell Limited Notes to the Accounts for the period from 26 April 2024 to 30 April 2025
4
Tangible fixed assets
Land & buildings
£
Cost or valuation
At cost
At 26 April 2024
-
Additions
263,312
At 30 April 2025
263,312
Depreciation
At 30 April 2025
-
Net book value
At 30 April 2025
263,312
5
Debtors
2025
£
Amounts falling due within one year
Other debtors
617
6
Creditors: amounts falling due within one year
2025
£
Other creditors
268,726
The creditors falling due within one year refers to the amounts due to the directors. The amounts due to the directors are unsecured, non-interest bearing and repayable on demand.
7
Average number of employees
During the period the average number of employees was 2.
- 8 -